Table 3:
Clinical outcomes captured through the U.S. CF Foundation National Patient Registry
| Variable | Period* | N | Experienced outcome (%) | OR | 95% CI | p value |
|---|---|---|---|---|---|---|
| P. aeruginosa positive | Baseline | 93 | 58 (62.4) | - | - | - |
| 0.5 – 1.5 years | 93 | 41 (44.1) | 0.095 | (0.011, 0.390) | <0.001 | |
| 4.5 – 5.5 years | 90 | 35 (38.9) | 0.045 | (0.001, 0.281) | <0.001 | |
| Any pulmonary exacerbation | Baseline | 94 | 34 (36.2) | - | - | - |
| 0.5 – 1.5 years | 94 | 15 (16.0) | 0.136 | (0.026, 0.454) | <0.001 | |
| 4.5 – 5.5 years | 90 | 15 (16.7) | 0.250 | (0.084, 0.628) | 0.001 | |
| Pulmonary exacerbation with hospitalization | Baseline | 94 | 32 (34.0) | - | - | |
| 0.5 – 1.5 years | 94 | 15 (16.0) | 0.190 | (0.048, 0.565) | 0.001 | |
| 4.5 – 5.5 years | 90 | 15 (16.7) | 0.273 | (0.090, 0.694) | 0.004 |
*
This data comes exclusively from the CFFPR. Patients are seen as clinically indicated at not at specified intervals as they were for all other data in this study, therefore intervals were used instead of precise time points. Baseline period is the one-year period before ivacaftor initiation. The other two periods are the number of years after ivacaftor initiation.